ViRexx completes enrollment for phase 3 trial of OvaRex MAb in ovarian cancer

By Lisa Kerner

Charlotte, N.C., June 22 - ViRexx Medical Corp. completed enrollment in the phase 3 trials by its licensing partner, Unither Pharmaceutical, of the monoclonal antibody OvaRex MAb for patients with stage 3 or stage 4 advanced ovarian cancer who have successfully completed front-line therapy.

The second of two identical phase 3 trials, Impact 2, reached its targeted enrollment of 177 patients earlier this week, while Impact 1 reached its enrollment target in December.

Both double-blind placebo-controlled trials, randomized 2:1 OvaRex MAb versus placebo studies are being conducted at more than 60 U.S. sites.

"With the completion of enrollment in the phase 3 trials we are one step closer to the potential commercialization of an important new therapeutic for women that suffer from ovarian cancer," chief executive officer Lorne Tyrrell said in a company news release.

"The next major milestone for this program will be the clinical data from these pivotal trials which is expected to be available in the mid portion of 2007."

ViRexx is an Edmonton, Alta.-based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and chronic viral infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.